Intra-Cellular Therapies Inc
NASDAQ:ITCI
Intra-Cellular Therapies Inc
NASDAQ:ITCI
Price:
131.87
USD
-0.04%
Market Closed
Market Cap:
$14B
Relative Value
The Relative Value of one
ITCI
stock under the Base Case scenario is
81.02
USD.
Compared to the current market price of 131.87 USD,
Intra-Cellular Therapies Inc
is
Overvalued by 39%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ITCI
Relative Value
Base Case
81.02
USD
Overvaluation 39%
Multiples Across Competitors
ITCI Competitors Multiples
Intra-Cellular Therapies Inc Competitors
Intra-Cellular Therapies Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Intra-Cellular Therapies Inc
NASDAQ:ITCI
|
14B USD | 20.6 | -187.6 | -111.9 | -111.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
879B USD | 13.5 | 42.6 | 28.7 | 30.7 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
573.4B USD | 6.1 | 21.4 | 14.9 | 18.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
257.8B CHF | 4.2 | 20 | 11.8 | 13.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
231.8B CHF | 5.3 | 21.4 | 13.2 | 17 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
222.8B GBP | 5.1 | 29.4 | 16.3 | 22.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
286.7B USD | 4.4 | 15.7 | 9.7 | 11.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
240.1B USD | 103.6 | -82.1 | 380.1 | 953.2 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.5 | 10.6 | 7.8 | 9.2 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.1B USD | 2.5 | 20.1 | 7.7 | 10.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120.2B USD | 2.5 | 17.1 | 7.2 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
